Metastatic colon carcinoma is the second leading cause of
death from malignancy in the United States. Eighty percent of
the patients who die of colon cancer have metastases in the
liver (1). Once hepatic metastases occur, surgery and chemotherapy
are the only currently available treatment modalities,
and the mean survival time is only 37 months (2). Therefore,
the development of alternative treatments for metastases of
colon cancer is needed to improve the clinical outcome of
patients.